Armata Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Shareholders

TL;DR

<b>Armata Pharmaceuticals will hold its 2024 Annual Meeting of Shareholders on June 12, 2024, to elect directors, vote on executive compensation, and ratify the auditor.</b>

AI Summary

Armata Pharmaceuticals, Inc. (ARMP) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Annual Meeting scheduled for June 12, 2024, at 8:30 a.m. PT. Shareholders will vote on electing seven nominees for director. Advisory vote on compensation of named executive officers is on the agenda. Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2024. Record date for voting is April 19, 2024.

Why It Matters

For investors and stakeholders tracking Armata Pharmaceuticals, Inc., this filing contains several important signals. Shareholders have the opportunity to influence board composition by electing director nominees. The meeting allows shareholders to provide feedback on executive compensation through an advisory vote.

Risk Assessment

Risk Level: low — Armata Pharmaceuticals, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual shareholder meeting and does not contain new financial or operational information that would indicate significant risk.

Analyst Insight

Shareholders should review the director nominees and executive compensation proposals before the June 12, 2024, meeting.

Key Numbers

• 7 — Nominees for Director (To be elected at the Annual Meeting.)
• 2025 — Director Term Expiration (Terms of elected directors will expire at the 2025 Annual Meeting.)
• 2024 — Fiscal Year End (Fiscal year for which Ernst & Young LLP is proposed as auditor.)

Key Players & Entities

• Armata Pharmaceuticals, Inc. (company) — Registrant and filer of the proxy statement.
• June 12, 2024 (date) — Date of the Annual Meeting of Shareholders.
• April 19, 2024 (date) — Record date for determining shareholders entitled to vote.
• Ernst & Young LLP (company) — Proposed independent registered public accounting firm.
• May 2, 2024 (date) — Date proxy materials will be mailed to shareholders.

FAQ

Risk Factors

• Compliance with SEC Filing Requirements [low — regulatory]: Failure to comply with SEC regulations regarding proxy statements could result in penalties.

Industry Context

Armata Pharmaceuticals operates in the biotechnology sector, focusing on developing treatments for serious infections.

Regulatory Implications

The filing adheres to the Securities Exchange Act of 1934, specifically Section 14(a) concerning proxy solicitations.

What Investors Should Do

1. Review the biographies and qualifications of the seven director nominees.
2. Understand the advisory vote proposal on the compensation of named executive officers.
3. Confirm the ratification of Ernst & Young LLP as the independent auditor for FY2024.

Key Dates

• 2024-06-12: Annual Meeting of Shareholders — Shareholders will vote on key corporate matters including director elections and executive compensation.
• 2024-04-19: Record Date — Determines which shareholders are eligible to vote at the Annual Meeting.
• 2024-05-02: Mailing of Proxy Materials — Shareholders will receive the proxy statement, proxy card, and annual report.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard proxy statement for an annual shareholder meeting, and does not represent a change from previous filings of this type.

Key Financial Figures

• $0.01 — hares of Armata common stock, par value $0.01 per share (" common stock ") (after giv
• $10.0 million — ment for an aggregate purchase price of $10.0 million (the " Financing "). After the Merger a

Filing Documents

• tm2410169-1_def14a.htm (DEF 14A) — 666KB
• bc_investment-4clr.jpg (GRAPHIC) — 55KB
• bc_investmenttsr-4clr.jpg (GRAPHIC) — 59KB
• bc_netincome-4clr.jpg (GRAPHIC) — 57KB
• bc_netloss-4clr.jpg (GRAPHIC) — 52KB
• px_armataproxy1pg1-bw.jpg (GRAPHIC) — 245KB
• px_armataproxy1pg2-bw.jpg (GRAPHIC) — 235KB
• sg_robinckramer-bw.jpg (GRAPHIC) — 8KB
• 0001104659-24-054149.txt (&nbsp;) — 1583KB

From the Filing

DEF 14A 1 tm2410169-1_def14a.htm DEF 14A tm2410169-1_def14a - none - 6.5937674s UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 ARMATA PHARMACEUTICALS, INC. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. ARMATA PHARMACEUTICALS, INC. 5005 McConnell Avenue Los Angeles, CA 90066 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 12, 2024 Dear Shareholder: You are cordially invited to attend the 2024 Annual Meeting of Shareholders (the " meeting " or the " Annual Meeting ") of Armata Pharmaceuticals, Inc., a Washington corporation (" Armata ," the " Company ," " we ," " our " or " us "). The meeting will be held at 8:30 a.m. (Pacific Time) on Wednesday, June 12, 2024 at our principal executive offices at 5005 McConnell Avenue, Los Angeles, California 90066, for the following purposes: 1. To elect seven nominees for director to serve one-year terms expiring at the 2025 Annual Meeting of Shareholders and upon their successors being duly elected and qualified; 2. To approve, on an advisory, non-binding basis, the compensation of our named executive officers; 3. To ratify the Audit Committee's selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024; and 4. To conduct any other business properly brought before the meeting or any adjournment or postponement thereof. These items of business are more fully described in the Proxy Statement accompanying this Notice. The record date for the meeting is April 19, 2024. Only shareholders of record at the close of business on that date may vote at the meeting or any adjournment thereof. We will first mail the Proxy Statement, accompanying proxy card and annual report to our shareholders on or about May 2, 2024. You may vote your shares by signing and dating the enclosed proxy card and returning it in the postage-paid envelope provided, whether or not you plan to attend the annual meeting. For your convenience, you may also vote your shares via the internet or by a toll-free telephone number by following the instructions on the enclosed proxy card. Voting by telephone, over the internet or by mailing a proxy card will not limit your right to participate in the meeting and vote your shares at the meeting. Even if you have voted by proxy, you may still vote at the in-person meeting if you participate in the meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must obtain a proxy issued in your name from that record holder. By Order of the Board of Directors, Robin C. Kramer Chair of the Board of Directors Los Angeles, California April 29, 2024 Important Notice Regarding the Availability of Proxy Materials for the 2024 Annual Meeting of Shareholders to be held on June 12, 2024: The notice of annual meeting, Proxy Statement and annual report to shareholders are available at https://investor.armatapharma.com/annual-reports-and-proxy or www.envisionreports.com/ARMP ARMATA PHARMACEUTICALS, INC. 5005 McConnell Avenue Los Angeles, California 90066 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 12, 2024 This Proxy Statement contains information related to the 2024 Annual Meeting of Shareholders (the " annual meeting " or the " meeting ") of Armata Pharmaceuticals, Inc. (" Armata ," the " Company ," " we ," " our " or " us ") to be held at 8:30 a.m. (Pacific Time) on Wednesday, June 12, 2024 at our principal executive offices at 5005 McConnell Avenue, Los Angeles, California 90066, and at any adjournments or postponements thereof. On or about May 2, 2024, we expect to begin mailing this Proxy Statement, accompanying proxy card and annual report to each holder of record of our common stock as of the close of business on April 19, 2024, the record date for the meeting. This Proxy Statement and accompanying proxy card summarize the information you need to know to vote by proxy or in person at the meeting. You do not need to attend the meeting in person in order to vote. Background On May 9, 2019, Armata, formerly known as AmpliPhi Biosciences Corporation and we refer to herein p

View Full Filing

View this DEF 14A filing on SEC EDGAR